Monitor ASCO 2026 presentations (May 29–June 2) for detailed efficacy/safety data on pumitamig and gotistobart. Positive data could drive near-term upside for BNTX, but no regulatory or commercial milestones are imminent. Watch for analyst reactions and potential partnership updates.
BNTX drugs
BNTX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 22 $92.14entry
- T+1 · 6mo ago +0.12%α −0.47% · $92.25
- T+5 · 6mo ago −0.48%α −2.14% · $91.70
- T+20 · 5mo ago −1.03%α +0.39% · $91.19
- T+60 · 3mo ago +0.66%α −2.53% · $92.75
Price Chart
How similar events traded
Executive Summary
BioNTech announced new clinical data for pumitamig (Phase 2/3 ROSETTA Lung-02 in 1L NSCLC) and gotistobart (Phase 2 PRESERVE-004 in platinum-resistant ovarian cancer) to be presented at ASCO 2026. The data show encouraging anti-tumor activity and durable overall survival, supporting the company's late-stage oncology pipeline of 25+ Phase 2/3 trials including 13 pivotal studies. No financial figures, guidance, or regulatory decisions were disclosed.
Key Facts
- Pumitamig (PD-L1 × VEGF-A bispecific) interim Phase 2 data from ROSETTA Lung-02 in 1L NSCLC shows encouraging anti-tumor activity across PD-L1 levels; third global dataset to show consistent activity.
- Gotistobart (anti-CTLA-4) Phase 2 PRESERVE-004 data in platinum-resistant ovarian cancer shows durable anti-tumor activity and clinically meaningful overall survival.
- BioNTech has 25+ Phase 2/3 trials, including 13 ongoing pivotal trials and novel-novel combination trials with ADCs.
- No revenue, EPS, guidance, or financial data were provided in the press release.
- Presentations at ASCO 2026 (May 29–June 2) include two oral presentations and four trial-in-progress posters.
Financial Impact
No financial figures disclosed; pipeline updates are non-financial catalysts.
Risk Factors
- Clinical data at ASCO may not meet expectations, leading to stock volatility.
- No financial guidance or revenue catalysts provided; pipeline remains early-stage with execution risk.
- Competition in NSCLC and ovarian cancer from established PD-1/CTLA-4 therapies and ADCs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299948 |
Track record
38 reports on BNTX
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20267d ago 6-K Neutral 4/10 Entry $87.21 Now $84.86 −2.69% settles Feb 8
- Nov 3, 202614d ago 6-K Neutral 5/10 No price data
- Nov 3, 202614d ago 6-K Neutral 5/10 No price data
- Nov 3, 202614d ago Press Release Neutral 5/10 Entry $86.92 Now $84.86 −2.37% settles Feb 1
- Oct 29, 202619d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $84.86 −4.79% settles Jan 27
- Oct 26, 202622d ago 6-K Bullish 5/10 Entry $86.86 Now $84.86 −2.30% settles Jan 22
- Oct 26, 202622d ago 6-K Bearish 5/10 Entry $86.86 Now $84.86 +2.30% settles Jan 22
- Oct 26, 202622d ago Press Release Bearish 6/10 Entry $86.86 Now $84.86 +2.30% settles Jan 22
- Oct 25, 202623d ago Press Release Bullish 6/10 Entry $86.86 Now $84.86 −2.30% settles Jan 22
- Oct 22, 202626d ago 6-K Neutral 5/10 Entry $89.67 Now $84.86 −5.36% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers